The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer.
Ontology highlight
ABSTRACT: Expression of estrogen and progesterone hormone receptors indicates a favorable prognosis due to the successful use of hormonal therapies such as tamoxifen and aromatase inhibitors. Unfortunately, 15-20% of patients will experience breast cancer recurrence despite continued use of tamoxifen. Drug resistance to hormonal therapies is of great clinical concern so it is imperative to identify novel molecular factors that contribute to tumorigenesis in hormone receptor positive cancers and/or mediate drug sensitivity. The hope is that targeted therapies, in combination with hormonal therapies, will improve survival and prevent recurrence. We have previously shown that the DEK oncogene, which is a chromatin remodeling protein, supports breast cancer cell proliferation, invasion and the maintenan
SUBMITTER: Privette Vinnedge LM
PROVIDER: S-EPMC3468546 | biostudies-literature | 2012
REPOSITORIES: biostudies-literature
ACCESS DATA